Trivalent inactivated influenza vaccine effective against influenza A(H3N2) variant viruses in children during the 2014/15 season, Japan

Norio Sugaya, Masayoshi Shinjo(H), Chiharu Kawakami, Yoshio Yamaguchi, Makoto Yoshida, Hiroaki Baba, Mayumi Ishikawa, Mio Kono, Shinichiro Sekiguchi, Takahisa Kimiya, Keiko Mitamura, Motoko Fujino, Osamu Komiyama, Naoko Yoshida, Kenichiro Tsunematsu, Atsushi Narabayashi, Yuji Nakata, Akihiro Sato, Nobuhiko Taguchi, Hisayo Fujita & 4 others Machiko Toki, Michiko Myokai, Ichiro Ookawara, Takao Takahashi

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

The 2014/15 influenza season in Japan was characterised by predominant influenza A(H3N2) activity; 99% of influenza A viruses detected were A(H3N2). Subclade 3C.2a viruses were the major epidemic A(H3N2) viruses, and were genetically distinct from A/New York/39/2012(H3N2) of 2014/15 vaccine strain in Japan, which was classified as clade 3C.1. We assessed vaccine effectiveness (VE) of inactivated influenza vaccine (IIV) in children aged 6 months to 15 years by test-negative case-control design based on influenza rapid diagnostic test. Between November 2014 and March 2015, a total of 3,752 children were enrolled: 1,633 tested positive for influenza A and 42 for influenza B, and 2,077 tested negative. Adjusted VE was 38% (95% confidence intervals (CI): 28 to 46) against influenza virus infection overall, 37% (95% CI: 27 to 45) against influenza A, and 47% (95% CI: -2 to 73) against influenza B. However, IIV was not statistically significantly effective against influenza A in infants aged 6 to 11 months or adolescents aged 13 to 15 years. VE in preventing hospitalisation for influenza A infection was 55% (95% CI: 42 to 64). Trivalent IIV that included A/New York/39/2012(H3N2) was effective against drifted influenza A(H3N2) virus, although vaccine mismatch resulted in low VE.

Fingerprint

H3N2 Subtype Influenza A Virus
Inactivated Vaccines
Influenza Vaccines
Human Influenza
Japan
Vaccines
Confidence Intervals
Influenza A virus
Virus Diseases
Orthomyxoviridae
Routine Diagnostic Tests
Hospitalization
Viruses

Keywords

  • Influenza
  • Influenza Virus
  • Laboratory surveillance
  • vaccine and immunization
  • vaccine effectiveness

ASJC Scopus subject areas

  • Epidemiology
  • Public Health, Environmental and Occupational Health
  • Virology

Cite this

Trivalent inactivated influenza vaccine effective against influenza A(H3N2) variant viruses in children during the 2014/15 season, Japan. / Sugaya, Norio; Shinjo(H), Masayoshi; Kawakami, Chiharu; Yamaguchi, Yoshio; Yoshida, Makoto; Baba, Hiroaki; Ishikawa, Mayumi; Kono, Mio; Sekiguchi, Shinichiro; Kimiya, Takahisa; Mitamura, Keiko; Fujino, Motoko; Komiyama, Osamu; Yoshida, Naoko; Tsunematsu, Kenichiro; Narabayashi, Atsushi; Nakata, Yuji; Sato, Akihiro; Taguchi, Nobuhiko; Fujita, Hisayo; Toki, Machiko; Myokai, Michiko; Ookawara, Ichiro; Takahashi, Takao.

In: Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, Vol. 21, No. 42, 20.10.2016.

Research output: Contribution to journalArticle

Sugaya, N, Shinjo(H), M, Kawakami, C, Yamaguchi, Y, Yoshida, M, Baba, H, Ishikawa, M, Kono, M, Sekiguchi, S, Kimiya, T, Mitamura, K, Fujino, M, Komiyama, O, Yoshida, N, Tsunematsu, K, Narabayashi, A, Nakata, Y, Sato, A, Taguchi, N, Fujita, H, Toki, M, Myokai, M, Ookawara, I & Takahashi, T 2016, 'Trivalent inactivated influenza vaccine effective against influenza A(H3N2) variant viruses in children during the 2014/15 season, Japan', Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, vol. 21, no. 42. https://doi.org/10.2807/1560-7917.ES.2016.21.42.30377
Sugaya, Norio ; Shinjo(H), Masayoshi ; Kawakami, Chiharu ; Yamaguchi, Yoshio ; Yoshida, Makoto ; Baba, Hiroaki ; Ishikawa, Mayumi ; Kono, Mio ; Sekiguchi, Shinichiro ; Kimiya, Takahisa ; Mitamura, Keiko ; Fujino, Motoko ; Komiyama, Osamu ; Yoshida, Naoko ; Tsunematsu, Kenichiro ; Narabayashi, Atsushi ; Nakata, Yuji ; Sato, Akihiro ; Taguchi, Nobuhiko ; Fujita, Hisayo ; Toki, Machiko ; Myokai, Michiko ; Ookawara, Ichiro ; Takahashi, Takao. / Trivalent inactivated influenza vaccine effective against influenza A(H3N2) variant viruses in children during the 2014/15 season, Japan. In: Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin. 2016 ; Vol. 21, No. 42.
@article{62b6aed8ed7a405bad4655fad1b785ee,
title = "Trivalent inactivated influenza vaccine effective against influenza A(H3N2) variant viruses in children during the 2014/15 season, Japan",
abstract = "The 2014/15 influenza season in Japan was characterised by predominant influenza A(H3N2) activity; 99{\%} of influenza A viruses detected were A(H3N2). Subclade 3C.2a viruses were the major epidemic A(H3N2) viruses, and were genetically distinct from A/New York/39/2012(H3N2) of 2014/15 vaccine strain in Japan, which was classified as clade 3C.1. We assessed vaccine effectiveness (VE) of inactivated influenza vaccine (IIV) in children aged 6 months to 15 years by test-negative case-control design based on influenza rapid diagnostic test. Between November 2014 and March 2015, a total of 3,752 children were enrolled: 1,633 tested positive for influenza A and 42 for influenza B, and 2,077 tested negative. Adjusted VE was 38{\%} (95{\%} confidence intervals (CI): 28 to 46) against influenza virus infection overall, 37{\%} (95{\%} CI: 27 to 45) against influenza A, and 47{\%} (95{\%} CI: -2 to 73) against influenza B. However, IIV was not statistically significantly effective against influenza A in infants aged 6 to 11 months or adolescents aged 13 to 15 years. VE in preventing hospitalisation for influenza A infection was 55{\%} (95{\%} CI: 42 to 64). Trivalent IIV that included A/New York/39/2012(H3N2) was effective against drifted influenza A(H3N2) virus, although vaccine mismatch resulted in low VE.",
keywords = "Influenza, Influenza Virus, Laboratory surveillance, vaccine and immunization, vaccine effectiveness",
author = "Norio Sugaya and Masayoshi Shinjo(H) and Chiharu Kawakami and Yoshio Yamaguchi and Makoto Yoshida and Hiroaki Baba and Mayumi Ishikawa and Mio Kono and Shinichiro Sekiguchi and Takahisa Kimiya and Keiko Mitamura and Motoko Fujino and Osamu Komiyama and Naoko Yoshida and Kenichiro Tsunematsu and Atsushi Narabayashi and Yuji Nakata and Akihiro Sato and Nobuhiko Taguchi and Hisayo Fujita and Machiko Toki and Michiko Myokai and Ichiro Ookawara and Takao Takahashi",
year = "2016",
month = "10",
day = "20",
doi = "10.2807/1560-7917.ES.2016.21.42.30377",
language = "English",
volume = "21",
journal = "Eurosurveillance",
issn = "1560-7917",
publisher = "Centre Europeen pour la Surveillance Epidemiologique du SIDA",
number = "42",

}

TY - JOUR

T1 - Trivalent inactivated influenza vaccine effective against influenza A(H3N2) variant viruses in children during the 2014/15 season, Japan

AU - Sugaya, Norio

AU - Shinjo(H), Masayoshi

AU - Kawakami, Chiharu

AU - Yamaguchi, Yoshio

AU - Yoshida, Makoto

AU - Baba, Hiroaki

AU - Ishikawa, Mayumi

AU - Kono, Mio

AU - Sekiguchi, Shinichiro

AU - Kimiya, Takahisa

AU - Mitamura, Keiko

AU - Fujino, Motoko

AU - Komiyama, Osamu

AU - Yoshida, Naoko

AU - Tsunematsu, Kenichiro

AU - Narabayashi, Atsushi

AU - Nakata, Yuji

AU - Sato, Akihiro

AU - Taguchi, Nobuhiko

AU - Fujita, Hisayo

AU - Toki, Machiko

AU - Myokai, Michiko

AU - Ookawara, Ichiro

AU - Takahashi, Takao

PY - 2016/10/20

Y1 - 2016/10/20

N2 - The 2014/15 influenza season in Japan was characterised by predominant influenza A(H3N2) activity; 99% of influenza A viruses detected were A(H3N2). Subclade 3C.2a viruses were the major epidemic A(H3N2) viruses, and were genetically distinct from A/New York/39/2012(H3N2) of 2014/15 vaccine strain in Japan, which was classified as clade 3C.1. We assessed vaccine effectiveness (VE) of inactivated influenza vaccine (IIV) in children aged 6 months to 15 years by test-negative case-control design based on influenza rapid diagnostic test. Between November 2014 and March 2015, a total of 3,752 children were enrolled: 1,633 tested positive for influenza A and 42 for influenza B, and 2,077 tested negative. Adjusted VE was 38% (95% confidence intervals (CI): 28 to 46) against influenza virus infection overall, 37% (95% CI: 27 to 45) against influenza A, and 47% (95% CI: -2 to 73) against influenza B. However, IIV was not statistically significantly effective against influenza A in infants aged 6 to 11 months or adolescents aged 13 to 15 years. VE in preventing hospitalisation for influenza A infection was 55% (95% CI: 42 to 64). Trivalent IIV that included A/New York/39/2012(H3N2) was effective against drifted influenza A(H3N2) virus, although vaccine mismatch resulted in low VE.

AB - The 2014/15 influenza season in Japan was characterised by predominant influenza A(H3N2) activity; 99% of influenza A viruses detected were A(H3N2). Subclade 3C.2a viruses were the major epidemic A(H3N2) viruses, and were genetically distinct from A/New York/39/2012(H3N2) of 2014/15 vaccine strain in Japan, which was classified as clade 3C.1. We assessed vaccine effectiveness (VE) of inactivated influenza vaccine (IIV) in children aged 6 months to 15 years by test-negative case-control design based on influenza rapid diagnostic test. Between November 2014 and March 2015, a total of 3,752 children were enrolled: 1,633 tested positive for influenza A and 42 for influenza B, and 2,077 tested negative. Adjusted VE was 38% (95% confidence intervals (CI): 28 to 46) against influenza virus infection overall, 37% (95% CI: 27 to 45) against influenza A, and 47% (95% CI: -2 to 73) against influenza B. However, IIV was not statistically significantly effective against influenza A in infants aged 6 to 11 months or adolescents aged 13 to 15 years. VE in preventing hospitalisation for influenza A infection was 55% (95% CI: 42 to 64). Trivalent IIV that included A/New York/39/2012(H3N2) was effective against drifted influenza A(H3N2) virus, although vaccine mismatch resulted in low VE.

KW - Influenza

KW - Influenza Virus

KW - Laboratory surveillance

KW - vaccine and immunization

KW - vaccine effectiveness

UR - http://www.scopus.com/inward/record.url?scp=85013758876&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85013758876&partnerID=8YFLogxK

U2 - 10.2807/1560-7917.ES.2016.21.42.30377

DO - 10.2807/1560-7917.ES.2016.21.42.30377

M3 - Article

VL - 21

JO - Eurosurveillance

JF - Eurosurveillance

SN - 1560-7917

IS - 42

ER -